Myriad Genetics, Inc. (MYGN)
| Market Cap | 457.58M |
| Revenue (ttm) | 824.50M |
| Net Income (ttm) | -365.90M |
| Shares Out | 94.44M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | 102.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 737,126 |
| Open | 4.840 |
| Previous Close | 4.830 |
| Day's Range | 4.780 - 4.925 |
| 52-Week Range | 3.760 - 8.590 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 7.64 (+57.69%) |
| Earnings Date | May 5, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price target is $7.64, which is an increase of 57.69% from the latest price.
News
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings con...
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, in...
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Healt...
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at...
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026
Leadership emphasized execution excellence and innovation, with new hires and reorganized teams driving growth in hereditary cancer, GeneSight, and prenatal segments. Product launches and operational improvements support guidance for sequential growth, while ASP stability and risk management remain key priorities.
Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference
Leadership highlighted a renewed strategy focused on cancer care, disciplined growth, and operational excellence. New product launches, strong hereditary cancer test growth, and stabilization in mental health and prenatal segments support a 6% revenue growth target for 2026, with profitability and execution as top priorities.
Myriad Genetics Earnings Call Transcript: Q4 2025
Q4 2025 revenue was $210M, with underlying growth of 4% year-over-year excluding GeneSight headwinds. Oncology and mental health segments showed strong volume growth, while prenatal is set to recover in 2026. Multiple new product launches and commercial investments are expected to drive growth.
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million...
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical val...
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings c...
Myriad Genetics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation outlined a sharpened focus on the cancer care continuum, with new leadership, disciplined execution, and a robust product pipeline including AI-enabled and MRD tests. Financial guidance projects steady growth, with key catalysts in hereditary cancer, prostate cancer, and strategic partnerships.
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CE...
Myriad Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference
Updated strategy focuses on the cancer care continuum, with new product launches in hereditary cancer, prenatal, and MRD testing. Operational improvements and partnerships drive growth, while financial discipline and expanded payer coverage support profitability.
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify...
Myriad Genetics Transcript: Wolfe Research Healthcare Conference 2025
Revised summary: The organization is in early stages of strategic transformation, focusing on the cancer care continuum with new leadership, disciplined resource allocation, and a robust product pipeline. Innovations include an ultra-sensitive MRD assay, AI-enabled digital pathology, and partnerships, with financial discipline and pharma collaborations supporting revenue.
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will particip...
Myriad Genetics Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 4% year-over-year to $205.7 million, but underlying growth was 5% after adjusting for headwinds. Strong test volume growth in hereditary cancer and mental health offset ASP pressures. The company reaffirmed 2025 guidance and is investing in new product launches and commercial expansion.
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expect...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings confe...
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recomme...
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowe...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI te...